Highlight,Sector Focus,: BridgeBio Pharma operates in the biopharmaceutical sector, with a focus on genetic conditions and oncology.,Insider Actions,: Notable insider share transactions have been ...

H.C. Wainwright analyst Raghuram Selvaraju raised the firm’s price target on BridgeBio (BBIO) to $53 from $49 and keeps a Buy rating on the ...

BridgeBio Pharma, Inc. (Nasdaq: BBIO) ("BridgeBio" or the "Company"), a commercial-stage biopharmaceutical company focused on genetic diseases, today ...

BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on ...

The sector is defensive, and biopharmaceuticals have, for the most part, limited tariff and transfer price exposure, he ...